Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Trial details
- Registry ID
- NCT03608033
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyNCT03608033 | Omeros Corporation | Phase 3 | Terminated | 2024-01-12Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |